In combination w/ rituximab for the treatment of adult patients w/ chronic lymphocytic leukaemia (CLL) who have received at least 1 prior therapy. As monotherapy for the treatment of patients w/ CLL w/ 17p deletion who have received at least 1 prior therapy, or patients w/ CLL w/o 17p deletion who have received at least 1 prior therapy & for whom there are no other available treatment options.
Assess risk of tumor lysis syndrome (TLS) in all patients. Pre-medicate w/ anti-hyperuricemics & ensure adequate hydration. Neutropenia. Monitor blood counts & for signs of infection. Do not administer live attenuated vaccine prior to, during, or after treatment. Embryo-fetal toxicity.